Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Methamphetamine Clear all
Terminated Phase 1 Interventional

Study of Pomaglumetad and Methamphetamine

NCT03106571
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 2 Interventional

Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

NCT01888835
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
Phillip Coffin, MD, MIA
Government
Eligibility
18 Years to 69 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 17, 2026, 10:40 PM EDT
Terminated Early Phase 1 Interventional

Methamphetamine-Quetiapine Interactions in Humans

NCT00567866
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Quetiapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 1 Interventional

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Placebo, Rivastigmine
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 17, 2026, 10:40 PM EDT
Terminated Phase 1 Interventional

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954
View directory record Official record
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine

NCT01529892
View directory record Official record
Conditions
Methamphetamine Metabolism, CYP2D6 Genotype
Interventions
A single oral 5 mg of duterium labeled methamphetamine
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

NCT01011829
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 17, 2026, 10:40 PM EDT
Not yet recruiting Phase 4 Interventional

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

NCT07584369
View directory record Official record
Conditions
HIV -1 Infection, Methamphetamine Use
Interventions
Oral Methamphetamine, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 17, 2026, 10:40 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin for Methamphetamine Use Disorder

NCT07774702
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Drug · Behavioral
Lead sponsor
Peter Hendricks
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

NCT03973489
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Magnetic resonance imaging (MRI), Methamphetamine Hydrochloride Tablets, Placebo oral tablet
Behavioral · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 17, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Modafinil for Methamphetamine Dependence

NCT00569374
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 17, 2026, 10:40 PM EDT